AP
Aptevo Therapeutics Inc.
APVO · NASDAQ
$1.84 -2.13% (-$0.04)
1M -23.65%
Market Cap $2.29M
P/E Ratio -
Div. Yield -
ROE 201.49%
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 0.38x
EV/FFO N/A
P/S N/A
Growth
19 /100
Declining Book val. growth 1.11%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 201.49%
ROA 181.89%
Asset turnover 0.00x
Debt
79 /100
Low Current ratio 2.08x
Debt/Equity 0.70x
Net debt/EBITDA N/A
Stability
10 /100
Unstable EPS volatility 166.54%
Profitable years 0
Beta 1.61x
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o APVO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jeffrey G. Lamothe
Employees
33
Headquarters
Seattle
Nadchodzące wydarzenia
05 LIS
Earnings
Upcoming earnings report